Enveric Biosciences, Inc. (ENVB) is a patient-first biotechnology company with a mission to revolutionize the standard approaches to health and wellness, particularly in the area of mental health, oncology supportive care, and neurology. The company is developing novel cannabinoids as well as innovative products to improve quality of life for cancer patients and other patients experiencing distressing side effects from conventional treatments.
Enveric Biosciences operates with a strong focus on the Science of Healing, combining advanced research in the fascinating field of cannabinoids with clinical applications aimed at providing supportive care and improving patients' lives. The company's approach of bringing together benchtop research and clinical practice is spearheaded by a team of experts experienced in the discovery and clinical development of chemical entities, natural health products, and medical devices.
The company's research is currently focused around cannabinoids—chemical compounds found in cannabis plants—with specific emphasis on treating side effects experienced by cancer patients, such as chemo-induced peripheral neuropathy, radiodermatitis, and chemotherapy-induced nausea and vomiting.
With a commitment to rigorous scientific methodology, clinical research, and patient-centered care, Enveric Biosciences follows all processes required to become an FDA-approved company. The aim is to not only alleviate the distressing side effects experienced by patients undergoing medical treatments but also to meaningfully improve patients' overall quality of life.
Enveric Biosciences operates from its headquarters in Florida and is listed on the Nasdaq Capital Market under the symbol "ENVB." As a publicly traded company, Enveric Biosciences positions its stakeholders at the core of its business strategy, prioritizing honesty and transparency in all its business dealings. The company disseminates frequent updates about its research processes, products under development, and other aspects of its operations to its investors, so they have clear, comprehensive, and up-to-date knowledge of its activities.
Enveric Biosciences believes in the therapeutic potential of cannabinoids and aims to push the envelope in capturing this potential for the benefit of patients worldwide. It is continuously on the lookout for innovative solutions in bio-health, and through rigorous clinical testing and research, it is committed to offering groundbreaking treatments that bring about a profound change in healthcare.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends

Enveric Biosciences reported its financial results for the third quarter ended September 30, 2026, alongside a comprehensive business update. The company emphasized its progress in advancing EB-003, a non-hallucinogenic neuroplastogenic candidate, towards a planned IND submission and first-in-human Phase 1 clinical trial. Preclinical data for EB-003 demonstrated brain penetration, activity distinct from DMT, and a non-hallucinogenic profile, supporting its potential as a differentiated treatment for psychiatric and neurological disorders.

Enveric Biosciences Inc. (NASDAQ: ENVB) has released favorable brain activity data for its lead psychiatric drug candidate, EB-003, from a quantitative electroencephalography (qEEG) study in mice. The study demonstrated that EB-003 effectively modulates brain activity without inducing the severe adverse effects like seizures or muscular spasms associated with traditional psychedelics such as DMT. These findings highlight EB-003's enhanced safety profile and support its advancement toward first-in-human clinical trials.

Enveric Biosciences is advancing its lead drug candidate, EB-003, a non-hallucinogenic neuroplastogen, with new preclinical findings supporting its progression toward human trials. The research indicates favorable ADMET properties (absorption, distribution, metabolism, excretion, and toxicity), suggesting a potentially lower risk of drug-drug interactions and suitability for oral administration. This development aims to separate the therapeutic benefits of psychedelic-inspired medicine from hallucinogenic effects, potentially making mental health treatments more accessible and easier to administer within existing healthcare systems.

Enveric Biosciences announced favorable preclinical results for its leading drug candidate, EB-003, a non-hallucinogenic compound aimed at treating psychiatric and neurological conditions. The IND-enabling studies showed a differentiated pharmacological profile, suggesting the potential for therapeutic benefits related to neuroplasticity with minimal safety concerns and no hallucinogenic effects. This milestone supports the continued advancement of EB-003 toward human clinical trials.

Enveric Biosciences announced positive results from IND-enabling ADMET studies for its lead neuroplastogenic candidate EB-003, demonstrating favorable oral absorption, systemic bioavailability, and a reduced potential for drug-drug interactions. These results are a significant milestone, supporting the safety profile of EB-003 and its advancement toward planned first-in-human clinical trials. The data indicate a differentiated pharmacological profile for EB-003, aiming to preserve therapeutic benefits while minimizing hallucinogenic impacts.
This article provides an overview of Enveric Biosciences Inc. (ENVB), including its current stock price, market capitalization, and key financial metrics. It highlights the company's focus on developing neuroplastogenic small-molecule therapeutics for psychiatric disorders and mentions recent favorable preclinical results for one of its candidates. The piece also includes recent news updates and market sentiment regarding ENVB.